Isosorbide dinitrate tablets

Isosorbide mononitrate (ISMN) is the main biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its main pharmacological action is to relax vascular smooth muscle. ISMN releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris. No carcinogenic and mutagenic phenomena were observed in animal experiments.

Isosorbide dinitrate.

This product is white tablets.

Long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretics to treat chronic congestive heart failure.

Tablets: 10-20 mg orally, 2 to 3 times a day. For severe cases, 40 mg can be used, 2 to 3 times a day.

Nitrate-induced vasodilatory headache may occur in the early stage of medication, but the symptoms usually disappear after taking it for several days. Facial flushing, dizziness, orthostatic hypotension and reflex tachycardia may also occur. Occasionally, blood pressure is significantly reduced, bradycardia, angina pectoris is aggravated and syncope may occur.

1. Patients with acute circulatory failure (shock, circulatory collapse); 2. Patients with severe hypotension (systolic blood pressure 90 mmHg); 3. Patients with acute myocardial infarction and low filling pressure (unless under the condition of continuous hemodynamic monitoring); 4. Patients with hypertrophic obstructive cardiomyopathy; 5. Patients with constrictive pericarditis or cardiac tamponade; 6. Patients with severe anemia; 7. Patients with glaucoma; 8. Patients with increased intracranial pressure; 9. Patients allergic to nitro compounds.

Precautions for children: All studies on this type of drug were conducted in adults. There is no data comparing the use of drugs in children and adults, so it is not recommended for use in children. Precautions for pregnancy and lactation: No toxic effects on embryos were observed in animal experiments, and it is not clear whether ISMN is excreted through breast milk. However, due to the lack of experience in the use of drugs in pregnant and lactating women, it should be used with caution. Precautions for the elderly: Elderly patients may be more sensitive to this type of drug and are more likely to experience reactions such as dizziness.

Combination with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensive drugs, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this class of drugs.

Seal and store in a cool, dry place.

5 mg

36 months

Shanghai Fudan Fuhua Pharmaceutical Co., Ltd.

• Founded in:

  1981-12-01

• Address:

  No. 1399 Shuguang Road, Minhang District, Shanghai

• Tax NO.:

  91310112132661556L

• Registered Funds:

  44.8 million yuan

• Email:

  Log in to view